KROS 8-K SEC Filing Analysis

Actionable Insight • Neutral

LLM returned non-JSON response. Review the filing manually.

DirectionNeutral

Confidencelow

Horizondays

Final — all horizons settled through T+60d ⚠ clustered

KROS ▼ -6.92% at T+60d

NEUTRAL call ✗ call lost -6.92% · α vs SPY -18.22% · entry $11.71 → $10.90

Entry anchored
Mar 4, 03:59 PM ET
via exchange tick

T+1d

-3.50%

call -3.50% · α -2.19%

$11.30

settled 7mo ago

T+5d

-6.15%

call -6.15% · α -3.91%

$10.99

settled 7mo ago

T+20d

+2.48%

call +2.48% · α +6.27%

$12.00

settled 6mo ago

T+60d

-6.92%

call -6.92% · α -18.22%

$10.90

settled 4mo ago

Price Chart

Loading chart...

Executive Summary

{ "summary": "Keros Therapeutics reported a full-year net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, primarily due to $205.4 million in license revenue from Takeda. The company also announced leadership changes and upcoming clinical trial milestones for rinvatercept in DMD and ALS. Cash reserves declined to $287.4 million from $559.9 million, largely due to a share repurchase and tender offer.", "sentiment": "mixed", "impactScore": 6

Financial Impact

Unknown

Risk Factors

Analysis may be incomplete

Market Snapshot

Exchange

Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001664710-26-000017
Document: kros-20260304.htm	0001664710-26-000017
Document: 0001664710-26-000017-index-headers.html	0001664710-26-000017
Document: 0001664710-26-000017-index.html	0001664710-26-000017
Document: 0001664710-26-000017.txt	0001664710-26-000017

17 reports for KROS

T+1T+5T+20T+60

100% Hit rate 4 of 4 directional calls best @ T+5▲ +10.72%Jul 30, 2026

Filters

Reports for KROS — sortable, filterable
	Type				Now
Sep 8, 2026 23d ago	8-K NEUTRAL ★ 4/10	$11.31 $11.04	▼ −2.39%	▼ −2.05%	$11.17 (−1.24%)
Aug 20, 2026 6w ago	Insider Cluster NEUTRAL ★ 4/10	$10.95 $11.23	▲ +2.56%	▲ +1.44%	$11.17 (+2.01%)
Aug 3, 2026 8w ago	8-K NEUTRAL ★ 4/10	$10.25 $10.64	▲ +3.80%	▲ +3.90%	$11.17 (+8.98%)
Aug 3, 2026 8w ago	Press Release NEUTRAL ★ 3/10	$10.25 $10.64	▲ +3.80%	▲ +3.90%	$11.17 (+8.98%)
Jul 30, 2026 9w ago	8-K BULLISH ★ 6/10	$10.07 $11.15	▲ +10.72%	▲ +7.21%	$11.17 (+10.92%)
Jul 22, 2026 10w ago	8-K NEUTRAL ★ 3/10	$10.14 $10.22	▲ +0.79%	▲ +0.31%	$11.17 (+10.16%)
Jun 17, 2026 15w ago	Insider Cluster NEUTRAL ★ 2/10	$10.65 $10.41	▼ −2.25%	▼ −0.59%	$11.17 (+4.88%)
Jun 8, 2026 16w ago	Insider Cluster NEUTRAL ★ 2/10	$10.07 $10.24	▲ +1.69%	▼ −0.72%	$11.17 (+10.92%)
May 14, 2026 20w ago	8-K BEARISH ★ 5/10	$10.99 $11.22	▼ −2.09%	▼ −2.81%	$11.17 (−1.64%)
May 14, 2026 20w ago	Press Release BEARISH ★ 6/10	$10.99 $11.22	▼ −2.09%	▼ −2.81%	$11.17 (−1.64%)

US Market Status

Market Open — Closes in 3h 40m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access